BioAtla Investor Presentation Deck

Phase 2 part 1 BA3011 NSCLC initial interim analysis confirms Phase 1 signal supports advancing preparations for part 2 in refractory NSCLC 60 ORR (%) 50 40 30 20 10 0 bicatla 33% 3/9 NSQ+SQ 43% 3/7 All NSQ 50% 2*/4 NSQ BA3011 monotherapy 33% NSQ - non-squamous; SQ - squamous Responses include 2 confirmed partial responses (*) and one confirmed complete response (**) 1**/3 NSQ BA3011 + nivolumab SQ 0/2 15 patients enrolled as of July 2022: 4 patients currently on treatment did not yet have the opportunity to be followed for 3 months; 2 patients are not efficacy-evaluable; 9 efficacy evaluable patients - All patients failed prior PD-1 treatment(s) – median prior lines of therapy = 2.5 BioAtla| Overview 19

View entire presentation